Genomic Valley Biotech Ltd

Genomic Valley Biotech Ltd has announced the closure of its trading window effective July 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure is to facilitate the consideration of the un-audited financial results for the quarter ended June 30, 2026. The trading window will reopen 48 hours after the announcement of these results. During this period, designated persons, including employees, directors, and their immediate relatives, are prohibited from trading in the company's shares and securities. The date for the board meeting to approve these financial results will be communicated separately.

Genomic Valley Biotech Ltd has appointed Mr. Navjyoti Kumar Jha as the internal auditor for the financial year 2026-27. The decision was made during a Board of Directors meeting held on May 29, 2026, where the board also approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. Mr. Jha has 26 years of experience and is not related to any director of the company.

Genomic Valley Biotech Ltd's Board of Directors approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board also approved the appointment of Mr. Navjyoti Kumar Jha as the Internal Auditor for the F.Y. 2026-27. The meeting commenced at 04:00 P.M. and concluded at 05:20 P.M.

Genomic Valley Biotech Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (standalone) for the quarter and year ended March 31, 2026. The trading window for dealing in the company's securities is closed from April 01, 2026, until 48 hours after the results are made public.

Genomic Valley Biotech Ltd promoters, including Yogesh Agrawal, Parul Agrawal, and Ojaswini Avantika (Promoter Group), have not made any encumbrances directly or indirectly during the financial year ended 31st March 2026. This declaration has been made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Genomic Valley Biotech Ltd. announces that its promoters, including Yogesh Agrawal, Parul Agrawal, and Ojaswini Avantika, have not made any encumbrances directly or indirectly during the financial year ended 31st March 2026. This disclosure was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Genomic Valley Biotech Ltd has announced the closure of the trading window for the quarter and year ending on March 31, 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The trading window will remain closed from April 1, 2026, until 48 hours after the announcement of the audited financial results for the quarter and year ended March 31, 2026. This means that employees, directors, key managerial personnel, designated persons, and their immediate relatives are prohibited from trading in the company's shares or securities during this period. The date of the board meeting for the declaration of the audited financial results will be announced in due course.

Genomic Valley Biotech Ltd has reported its financial results for the quarter and nine months ended 31 December 2025. The company's revenue from operations stands at 5,00,000, 23,00,000, and 58,80,795 for the respective periods. The total revenue for the same periods is 5,00,000, 23,00,000, and 84,384,054. The total expenses for the respective periods are 3,94,794, 8,66,951, and 43,05,297. The company's profit/loss for the period is 3,84,786.

Genomic Valley Biotech Ltd. has reported its financial results for the quarter and nine months ended 31 December 2025. The company's revenue from operations stands at 5,00,000 for the current quarter, a significant increase from the previous year. The total revenue for the current period is 58,80,795. The company's total expenses amount to 15,75,499, resulting in a comprehensive income of 3,84,786. The Board of Directors also accepted the resignation of Mr. Ashok Kumar from his directorship. The meeting was held on 15 January 2026.

Genomic Valley Biotech Ltd has announced that its Board of Directors will meet on January 15, 2026, to consider and approve the unaudited financial results (standalone) for the quarter and nine months ended 31st December 2025. The meeting will also consider any other matter with the permission of the chairman. The 'trading window' for dealing in securities of the Company is closed from January 01, 2026, until the end of 48 hours after the results are made public on January 15, 2026, for the Directors, KMPs, Promoters & Promoters Group and Designated Persons covered under the code.